WallStreetZenWallStreetZen

NASDAQ: AKRO
Akero Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for AKRO

Based on 4 analysts offering 12 month price targets for Akero Therapeutics Inc

Min Forecast
$64.00+47.26%
Avg Forecast
$72.50+66.82%
Max Forecast
$78.00+79.48%

Should I buy or sell AKRO stock?

Based on 4 analysts offering ratings for Akero Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 75%
Buy
1 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although AKRO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates AKRO as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their AKRO stock forecasts and price targets.

AKRO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-04
lockedlocked$00.00+00.00%2025-08-04
lockedlocked$00.00+00.00%2025-05-27
lockedlocked$00.00+00.00%2025-05-13

1 of 1

Forecast return on equity

Is AKRO forecast to generate an efficient return?

Company
-24.57%
Industry
129.65%
Market
-52.5%
AKRO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AKRO forecast to generate an efficient return on assets?

Company
-23.04%
Industry
47.74%
AKRO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AKRO earnings per share forecast

What is AKRO's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$3.82
Avg 2 year Forecast
-$4.12
Avg 3 year Forecast
-$4.46

AKRO revenue forecast

What is AKRO's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$199.3M
Avg 2 year Forecast
$416.3M
Avg 3 year Forecast
$870.0M

AKRO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AKRO$43.46$72.50+66.82%Strong Buy
AAPG$40.46N/AN/A
MLTX$52.62$69.00+31.13%Strong Buy
ZLAB$32.80$65.00+98.17%Strong Buy
KYMR$46.99$59.00+25.56%Strong Buy
View Top Biotech Stocks

Akero Therapeutics Stock Forecast FAQ

Is Akero Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: AKRO) stock is to Strong Buy AKRO stock.

Out of 4 analysts, 3 (75%) are recommending AKRO as a Strong Buy, 1 (25%) are recommending AKRO as a Buy, 0 (0%) are recommending AKRO as a Hold, 0 (0%) are recommending AKRO as a Sell, and 0 (0%) are recommending AKRO as a Strong Sell.

If you're new to stock investing, here's how to buy Akero Therapeutics stock.

What is AKRO's earnings growth forecast for 2025-2027?

(NASDAQ: AKRO) Akero Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.16%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.22%.

Akero Therapeutics's earnings in 2025 is -$269,441,000.On average, 8 Wall Street analysts forecast AKRO's earnings for 2025 to be -$304,824,044, with the lowest AKRO earnings forecast at -$352,351,659, and the highest AKRO earnings forecast at -$286,186,076. On average, 6 Wall Street analysts forecast AKRO's earnings for 2026 to be -$328,037,801, with the lowest AKRO earnings forecast at -$350,757,308, and the highest AKRO earnings forecast at -$319,667,456.

In 2027, AKRO is forecast to generate -$355,277,294 in earnings, with the lowest earnings forecast at -$391,413,269 and the highest earnings forecast at -$297,346,536.

What is AKRO's revenue growth forecast for 2028-2030?

(NASDAQ: AKRO) Akero Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.83%.

Akero Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast AKRO's revenue for 2028 to be $15,884,522,998, with the lowest AKRO revenue forecast at $15,884,522,998, and the highest AKRO revenue forecast at $15,884,522,998. On average, 1 Wall Street analysts forecast AKRO's revenue for 2029 to be $33,186,424,391, with the lowest AKRO revenue forecast at $33,186,424,391, and the highest AKRO revenue forecast at $33,186,424,391.

In 2030, AKRO is forecast to generate $69,357,474,603 in revenue, with the lowest revenue forecast at $69,357,474,603 and the highest revenue forecast at $69,357,474,603.

What is AKRO's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: AKRO) forecast ROA is -23.04%, which is lower than the forecast US Biotechnology industry average of 47.74%.

What is AKRO's Price Target?

According to 4 Wall Street analysts that have issued a 1 year AKRO price target, the average AKRO price target is $72.50, with the highest AKRO stock price forecast at $78.00 and the lowest AKRO stock price forecast at $64.00.

On average, Wall Street analysts predict that Akero Therapeutics's share price could reach $72.50 by Sep 4, 2026. The average Akero Therapeutics stock price prediction forecasts a potential upside of 66.82% from the current AKRO share price of $43.46.

What is AKRO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: AKRO) Akero Therapeutics's current Earnings Per Share (EPS) is -$3.75. On average, analysts forecast that AKRO's EPS will be -$3.82 for 2025, with the lowest EPS forecast at -$4.42, and the highest EPS forecast at -$3.59. On average, analysts forecast that AKRO's EPS will be -$4.12 for 2026, with the lowest EPS forecast at -$4.40, and the highest EPS forecast at -$4.01. In 2027, AKRO's EPS is forecast to hit -$4.46 (min: -$4.91, max: -$3.73).

What is AKRO's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: AKRO) forecast ROE is -24.57%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.